1. Home
  2. BGLC vs PRPO Comparison

BGLC vs PRPO Comparison

Compare BGLC & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • PRPO
  • Stock Information
  • Founded
  • BGLC N/A
  • PRPO N/A
  • Country
  • BGLC Malaysia
  • PRPO United States
  • Employees
  • BGLC 30
  • PRPO N/A
  • Industry
  • BGLC Medical Specialities
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • BGLC Health Care
  • PRPO Industrials
  • Exchange
  • BGLC Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • BGLC 9.2M
  • PRPO 8.8M
  • IPO Year
  • BGLC N/A
  • PRPO N/A
  • Fundamental
  • Price
  • BGLC $0.51
  • PRPO $5.25
  • Analyst Decision
  • BGLC
  • PRPO
  • Analyst Count
  • BGLC 0
  • PRPO 0
  • Target Price
  • BGLC N/A
  • PRPO N/A
  • AVG Volume (30 Days)
  • BGLC N/A
  • PRPO 9.4K
  • Earning Date
  • BGLC N/A
  • PRPO 08-15-2024
  • Dividend Yield
  • BGLC N/A
  • PRPO N/A
  • EPS Growth
  • BGLC N/A
  • PRPO N/A
  • EPS
  • BGLC N/A
  • PRPO N/A
  • Revenue
  • BGLC N/A
  • PRPO $15,812,000.00
  • Revenue This Year
  • BGLC N/A
  • PRPO $75.18
  • Revenue Next Year
  • BGLC N/A
  • PRPO N/A
  • P/E Ratio
  • BGLC N/A
  • PRPO N/A
  • Revenue Growth
  • BGLC N/A
  • PRPO 61.64
  • 52 Week Low
  • BGLC N/A
  • PRPO $4.31
  • 52 Week High
  • BGLC N/A
  • PRPO $8.99
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 54.22
  • PRPO 51.79
  • Support Level
  • BGLC $0.46
  • PRPO $4.32
  • Resistance Level
  • BGLC $0.55
  • PRPO $5.80
  • Average True Range (ATR)
  • BGLC 0.04
  • PRPO 0.43
  • MACD
  • BGLC 0.01
  • PRPO 0.06
  • Stochastic Oscillator
  • BGLC 44.29
  • PRPO 63.09

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: